In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
ICON partners with US Government for clinical trials of Covid-19 vaccines
The article on Clinical Trials Arena reports that ICON will conduct a phase 2b clinical trial for the US BARDA-selected Covid-19 vaccine candidate as part of Project NextGen.
-
BARDA, ICON partner to execute next-gen COVID vaccine trial
This news article from Contract Pharma reports that ICON will execute a Phase 2b clinical trial to assess the relative efficacy of a next generation COVID-19 vaccine.
-
ICON in pact with BARDA for next-gen COVID vaccine trial
The piece from Seeking Alpha highlights that the trial is designed to evaluate the vaccine candidate selected by BARDA, which functions as part of the Administration for Strategic Preparedness and Response under the U.S. Department of Health and Human Services.
-
ICON to partner with US government agency to test COVID vaccine candidates
This news article from Reuters outlines that, as part of the collaboration with Biomedical Advanced Research and Development Authority, ICON will conduct a mid-stage trial of 10,000 participants to assess the efficacy of a next generation COVID-19 vaccine relative to currently available shots.
-
Innovative laboratory testing methods for clinical monitoring of cell therapies using flow cytometry DDPCR and QPCR assays
In this article from International Biopharmaceutical Industry, Dr. Chad Galderisi, Vice President and Global Medical Director for ICON Specialty Laboratories explores how unique applications of PCR and flow cytometry can be used to provide critical and complementary data that is needed to bring new life-saving treatment options to patients.
Published by International Biopharmaceutical Industry Journal Volume 6 Issue 3
-
ICON to conduct U.S. government trial of next-gen COVID-19 vaccines
This news article, published on FIERCE Biotech, highlights that ICON is partnering with the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) to conduct a clinical trial to evaluate next-generation vaccines for COVID-19.
-
Improving health equity and diversity throughout the life sciences
As life sciences companies look for ways to improve diversity, equity and inclusion both within their organisations and in healthcare as a whole,PM360turned to 10 experts in the space to ask them how. In this article, Joshua Bueller, Account VP and Senior Strategy Consultant at ICON, describes how pharma companies can gain a better understanding into the needs of underrepresented and underserved groups using a patient-centric, data-driven approach.
-
Why pursuit of meaningful Alzheimer’s therapies is gathering pace
In this article in Neuro Rehab Times, ICON expert, Peter Schüler, reflects on the potential implications of new Alzheimer’s therapies on the research landscape.
-
AI is game changer for toughest areas of drug discovery
In this piece from Forbes, Dr. Greg Licholai, Chief Medical and Chief Innovation Officer talks about how, with proper use, AI can help accelerate a new era of medical research.
-
Patient-first technology development increasing patient centricity
This article by Carrye Nibblelink, Executive Director, Decentralised Clinical Trial Solutions in the Journal of mHealth explores how the ICON Digital Platform engages patients throughout their clinical trial journey.
Copyright 2023 The Journal of mHealth (Simidics Ltd)
